induced pluripotent stem cells

[Bayer AG (BusinessWire, Inc.)] Bayer AG announced that BlueRock Therapeutics successfully administered the first dose of its investigational pluripotent stem cell-derived dopaminergic neurons, named DA01, to a Parkinson’s disease patient in their open-label Phase I clinical safety and tolerability study.

[Nature Communications] To efficiently cluster hPSC-derived pancreatic progenitors into 3D structures, scientists discovered 10 chemicals that not only retained the pancreatic progenitors in 3D clusters but also enhanced their potentiality towards NKX6.1+/INS+β cells.

[Molecular Therapy-Methods & Clinical Development] Scientists devised a single cut gene editing method using a compact Staphylococcus aureus Cas9 to restore the open reading frame of exon 51, the most commonly affected out-of-frame exon in Duchenne muscular dystrophy. Editing of exon 51 in cardiomyocytes revealed a strong preference for exon reframing via a two nucleotide deletion.

[Proceedings of the National Academy of Sciences of the United States of America] Scientists employed highly sensitive fluorescence spectroscopy approaches, in combination with a fluorescent β‐AR antagonist, to determine the presence and dynamics of the endogenous receptors on the outer plasma membrane as well as on the T-tubular network of intact adult cardiomyocytes.

[Sorrento Therapeutics, Inc.] Sorrento Therapeutics, Inc. announced that the Company has entered into an additional collaborative agreement with NextGenNK Competence Center-associated research groups at the Department of Medicine, Huddinge, Karolinska Institutet  in Stockholm, Sweden, aimed at producing novel cell-based therapeutics using natural killer cells derived from induced pluripotent stem cells.

[Cell Stem Cell] The authors discussed the potential of “organ-on-a-chip” systems to study regenerative therapies with focus on three distinct organ systems: cardiac, respiratory, and hematopoietic.